Skip to content
DataLookout
Menu

NCT04713046

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 15 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words
    • Primary and study completion pushed from Oct 1, 2026 to Dec 1, 2026
    • Secondary endpoints: details revised at 3 of 5 entries
  2. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised
    v15
  3. Minor Site contact updatedv14
  4. Notable Primary and study completion dates: Oct 1, 2025 to Oct 1, 2026v13
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary and study completion dates: Aug 1, 2025 to Oct 1, 2025
    • Start date changed from estimate of Oct 1, 2023 to Oct 18, 2023
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Notable Start date: Aug 1, 2023 to Oct 1, 2023v10
  2. Notable Start date: May 15, 2023 to Aug 1, 2023
    • Primary and study completion dates: May 31, 2025 to Aug 1, 2025
    v9
  3. Notable Start date: Mar 15, 2023 to May 15, 2023
    • Primary and study completion dates: Mar 31, 2025 to May 31, 2025
    v8
  4. Notable Primary and study completion dates: Mar 31, 2024 to Mar 31, 2025
    • Start date: Nov 15, 2022 to Mar 15, 2023
    v7
  5. Notable Start date: Sep 15, 2022 to Nov 15, 2022v6
  6. Notable Start date: Jun 15, 2022 to Sep 15, 2022
    • Primary completion date: Dec 31, 2023 to Mar 31, 2024
    • Study completion date: Dec 31, 2024 to Mar 31, 2024
    v5
  7. Notable Primary completion date: Dec 31, 2022 to Dec 31, 2023
    • Study completion date: Dec 31, 2022 to Dec 31, 2024
    v4
  8. Notable Start date: Jan 15, 2022 to Jun 15, 2022v3
  9. Notable Start date: Jul 1, 2021 to Jan 15, 2022v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Timeframe: 12 months
Maximum Tolerated Dose (MTD) of Allogeneic CD4+ T cell Infusion
Timeframe: 12 months

Secondary (5)

Number of toxicities as assessed by the NCI CTCAE version 5.0
Progression-free survival (PFS) of allogeneic CD4+ T cell Infusion and allogeneic BMT
Overall survival (OS) of allogeneic CD4+ T cell Infusion and allogeneic BMT
Overall Response of allogeneic CD4+ T cell Infusion and allogeneic BMT
Incidence of acute graft versus host disease (GVHD)

Arms and interventions

Allogeneic bone marrow transplantExperimental

non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.

CD8-depleted donor lymphocyte infusion (DLI) per dose escalation schemeExperimental

CD8-depleted donor lymphocyte infusion per dose escalation scheme from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.

Biologicals: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16, Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16

Sites

1 site in 1 country

  • Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland, United States